Lercanidipin Genericon

Lercanidipine hydrochloride, the active ingredient in Lercanidipin Genericon, is a calcium channel blocker (dihydropyridine) presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercanidipin Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used to manage elevated blood pressure. - Hypertension: lowers systolic and diastolic pressure in adults with primary hypertension. - Essential hypertension: assists patients in reaching guideline‑recommended blood pressure targets. - Isolated systolic hypertension: provides arterial vasodilation to reduce isolated systolic elevations.

Lercanidipine may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually resolves with continued therapy. - Peripheral edema: swelling of ankles or lower legs due to vasodilation. - Dizziness or light‑headedness, particularly after standing. - Tachycardia or palpitations: increased heart rate in some patients.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Angioedema: swelling of face, lips, tongue, or airway requiring urgent care. - Myocardial infarction: rare reports of acute coronary events. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylactic reaction: life‑threatening allergic response.

Before initiating therapy, consider the following safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: use with caution; dose adjustment may be needed. - Concomitant antihypertensives: assess risk of additive hypotensive effect. - Elderly patients: start at lower dose and monitor for dizziness. - Discontinuation: avoid abrupt cessation; taper if clinically indicated. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Concurrent use with other potent antihypertensives: can cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely): - Grapefruit juice: may elevate drug levels modestly. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs: can blunt antihypertensive effect. - Diuretics: may increase risk of electrolyte imbalance when combined.